Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12503
Title: Contrast-enhanced ultrasonography to evaluate changes in renal cortical microcirculation induced by noradrenaline: a pilot study.
Authors: Schneider, Antoine G;Goodwin, Mark D;Schelleman, Anthony;Bailey, Michael J;Johnson, Lynne;Bellomo, Rinaldo
Affiliation: Intensive Care Unit, Austin Health, 145 Studley road, Heidelberg, VIC, 3084, Australia. antoine.schneider@chuv.ch.
Radiology department, Austin Health, Heidelberg, VIC, Australia. mark.goodwin@austin.org.au.
Radiology department, Austin Health, Heidelberg, VIC, Australia. anthony.schelleman@austin.org.au.
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. michael.bailey@monash.edu.
Radiology department, Austin Health, Heidelberg, VIC, Australia. lynne.johnson@austin.org.au.
Intensive Care Unit, Austin Health, 145 Studley road, Heidelberg, VIC, 3084, Australia. rinaldo.bellomo@austin.org.au.
Issue Date: 2-Dec-2014
Citation: Critical Care (london, England) 2014; 18(6): 653
Abstract: We used contrast-enhanced ultrasound (CEUS) to estimate the effect of an increase in mean arterial pressure (MAP) induced by noradrenaline infusion on renal microvascular cortical perfusion in critically ill patients.Twelve patients requiring a noradrenaline infusion to maintain a MAP more than 60 mmHg within 48 hours of intensive care unit admission were included in the study. Renal CEUS scans with destruction-replenishment sequences and Sonovue® (Bracco, Milano Italy) as a contrast agent, were performed at baseline (MAP 60 to 65 mmHg) and after a noradrenaline-induced increase in MAP to 80 to 85 mmHg.There was no adverse effect associated with ultrasound contrast agent administration or increase in noradrenaline infusion rate. Adequate images were obtained in all patients at all study times. To reach the higher MAP target, median noradrenaline infusion rate was increased from 10 to 14 μg/min. Noradrenaline-induced increases in MAP were not associated with a significant change in overall CEUS derived mean perfusion indices (median perfusion index 3056 (interquartile range: 2438 to 6771) arbitrary units (a.u.) at baseline versus 4101 (3067 to 5981) a.u. after MAP increase, P = 0.38). At individual level, however, we observed important heterogeneity in responses (range -51% to +97% changes from baseline).A noradrenaline-induced increase in MAP was not associated with an overall increase in renal cortical perfusion as estimated by CEUS. However, at individual level, such response was heterogeneous and unpredictable suggesting great variability in pressure responsiveness within a cohort with a similar clinical phenotype.
Internal ID Number: 25439317
URI: http://ahro.austin.org.au/austinjspui/handle/1/12503
DOI: 10.1186/s13054-014-0653-3
URL: http://www.ncbi.nlm.nih.gov/pubmed/25439317
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
25439317.pdf1.44 MBAdobe PDFThumbnail
View/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.